This site is intended for healthcare professionals
Primary Hyperoxaluria Type 1
Diagnosis and management of primary hyperoxaluria type 1
Declaration of sponsorship Alnylam Pharmaceuticals

PH1 overview

Declaration of sponsorship Alnylam Pharmaceuticals
Read time: 30 mins
Last updated:30th Mar 2023
Published:5th Apr 2021

Primary hyperoxaluria type 1 (PH1) is a life-limiting disease of oxalate overproduction, in which patients can present with a wide spectrum of clinical manifestations, from kidney stones to end-stage kidney disease (ESKD) to oxalate deposition in the eyes, heart and skin1,2. Early intervention is imperative and this resource will detail the pathophysiology of PH1, offer typical patient presentations and give a review of current management options.

GEO restriction imageThis resource is only available for healthcare professionals outside of your region. Click below to browse other relevant learning materials.

Urology resources

Welcome:
Updates in your area
of interest
Articles your peers
are looking at
Bookmarks
saved
Days to your
next event

Developed by EPG Health for Medthority.com, with all content provided by Alnylam Pharmaceuticals. Learning Zone sponsored and funded by Alnylam Pharmaceuticals. Please note that this material is intended for healthcare professionals only. 

Date of preparation: November 2024 │ OXL-CEMEA-00012

© Copyright 2021